Symbiotec Pharmalab IPO: Price Band, Dates, GMP, Allotment and Key Details
Symbiotec Pharmalab IPO opened for subscription on August 24, 2026, allowing investors to participate in the mainboard public issue of the pharmaceutical API manufacturer. The IPO has a price band of ₹938 to ₹988 per equity share and will remain open until August 27, 2026.
The issue includes a fresh issue as well as an Offer for Sale (OFS), with the total issue size reported at approximately ₹1,757 crore.
Symbiotec Pharmalab IPO: Key Details
Here are the important details investors should know:
- IPO Open Date: August 24, 2026
- IPO Close Date: August 27, 2026
- Price Band: ₹938–₹988 per share
- Face Value: ₹2 per share
- Issue Size: Approximately ₹1,757 crore
- Fresh Issue: Approximately ₹150 crore
- Offer for Sale: Approximately 1,62,65,181 equity shares
- IPO Type: Book-Built Issue
- Lot Size: 15 shares
- Listing: BSE and NSE
- IPO Listing Date: September 1, 2026, as per the reported schedule
According to IPO Watch, the minimum application is for one lot of 15 shares. At the upper price band of ₹988, investors would need ₹14,820 for one lot, excluding applicable charges.
Symbiotec Pharmalab IPO Important Dates
The reported IPO timeline is:
- IPO Opens: August 24, 2026
- IPO Closes: August 27, 2026
- Basis of Allotment: August 28, 2026
- Refund Initiation: August 31, 2026
- Shares Credited to Demat: August 31, 2026
- Expected Listing: September 1, 2026
Investors can check their allotment after the basis of allotment is finalised.
Check IPO Allotment Status:
Check IPO Allotment Status – FutureSenseIndia
What Does Symbiotec Pharmalab Do?
Symbiotec Pharmalab operates in the pharmaceutical and biotechnology sector, with a focus on specialised pharmaceutical ingredients.
The company primarily manufactures corticosteroid and steroidal hormone Active Pharmaceutical Ingredients (APIs) used in pharmaceutical products.
According to the IPO information, the company has developed from a laboratory-scale steroid manufacturer into a more integrated global business and has established a significant position in the global corticosteroid and steroidal-hormone API market.
The company was also described as a global leader by volume in FY2025 in the production of corticosteroid and steroidal-hormone APIs.
Symbiotec Pharmalab IPO: Fresh Issue vs OFS
The IPO consists of two components: a fresh issue and an Offer for Sale.
The fresh issue is approximately ₹150 crore, while the OFS comprises approximately 1.6265 crore equity shares.
The distinction is important for investors.
Money raised through the fresh issue goes to the company, while proceeds from the OFS are received by the selling shareholders.
Therefore, the total IPO size of approximately ₹1,757 crore should not be interpreted as the entire amount being raised by Symbiotec Pharmalab for its own business.
Symbiotec Pharmalab IPO GMP
The Grey Market Premium (GMP) is one of the most closely watched indicators ahead of the IPO listing.
According to the IPO Watch update available on August 24, 2026, Symbiotec Pharmalab IPO GMP was reported at ₹409 per share. The reported GMP had increased from ₹260 on August 20 to ₹320 on August 21, ₹380 on August 22, and ₹409 on August 24.
At the upper IPO price of ₹988, a GMP of ₹409 implies an indicative grey-market price of around ₹1,397 per share.
This represents an indicative premium of approximately 41.4% over the upper price band.
Check Live Symbiotec Pharmalab IPO GMP
GMP can change quickly, particularly during the subscription period. Investors should check the latest figure rather than relying on an earlier GMP.
Check Live IPO GMP – FutureSenseIndia
Important: GMP is an unofficial market indicator and does not guarantee the actual listing price or listing gains.
What Investors Should Check Before Applying
While GMP can provide an indication of market sentiment, it should not be the primary reason for applying to an IPO.
Investors should also examine:
1. Business Model
Understand Symbiotec’s pharmaceutical API portfolio, manufacturing capabilities and customer base.
2. Financial Performance
Review the company’s revenue, EBITDA, profit, margins and cash flows over multiple financial years.
3. IPO Valuation
Compare the IPO valuation with the company’s earnings and valuations of comparable listed pharmaceutical and API companies.
4. Fresh Issue and OFS
Investors should understand how much capital is actually being raised by the company and how much represents an OFS by existing shareholders.
5. GMP
GMP may indicate short-term market sentiment but is not a guaranteed indicator of listing performance.
6. Risk Factors
Investors should carefully read the company’s RHP for risks related to regulatory approvals, manufacturing, customer concentration, exports, pricing pressure, and the pharmaceutical API industry.
RHP Click here
Symbiotec Pharmalab IPO: Investor Takeaway
The Symbiotec Pharmalab IPO is a mainboard issue of approximately ₹1,757 crore, with a price band of ₹938–₹988 per share. The IPO opened on August 24 and closes on August 27, 2026.
The company operates in a specialised pharmaceutical API segment, particularly corticosteroid and steroidal-hormone APIs.
The reported ₹409 GMP on August 24 points to strong grey-market interest at that point in time. However, GMP is unofficial and can move significantly before listing.
For investors, the more important factors remain the company’s financial performance, business prospects, valuation, competitive position, risks and use of IPO proceeds.
Disclaimer: Grey Market Premium is unofficial, unregulated, and subject to change. It should not be considered a guarantee of the IPO’s listing price or future returns. Investors should read the company’s official offer documents, including the RHP, and evaluate the company’s fundamentals, valuation, and risk factors before making an investment decision. This article is for informational and educational purposes only and should not be considered investment advice.